Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV niraparib maintenance therapy in BRCA wild-type newly diagnosed advanced ovarian cancer in Korea
KCT0006964Phase 4Not yet recruiting
- Sponsor
- Takeda
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of niraparib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Takeda. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0006964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006964.